Korro Bio, Inc.
NASDAQ:KRROBiotechnology
+$1.76 today
- Market cap
- $170.75M
- Beta
- 2.10
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$9.79
Volume 0.16M
Average 0.15M
KRRO Total Non-current Assets
All assets not expected to be converted to cash within one year.
Korro Bio, Inc.NASDAQ: KRRO
Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Total non-current assets falls 21.6% from a year ago
Total non-current assets stood at $63.46M at the end of Q1 FY2026, down 21.6% from a year earlier and up 103.8% from the prior quarter. Over 3 fiscal years it compounded at +23.2% a year.
Context
- Total non-current assets amounted to 34.6% of total assets at the end of Q1 FY2026, down 5.5 pp from a year earlier.
- Total non-current assets increased in 2 of the last 3 fiscal years.
What to watch
Whether total non-current assets keeps falling in the next quarterly balance sheet after a -21.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 31.13M USD
- Year-over-year change
- -67.1%
- 4-year CAGR
- -11.4%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 31.13M | -67.1% |
| FY2024 | 2024-12-31 | 94.71M | +93.5% |
| FY2023 | 2023-12-31 | 48.94M | +193.7% |
| FY2022 | 2022-12-31 | 16.66M | -67.1% |
| FY2021 | 2021-12-31 | 50.61M | — |
Total Non-current Assets vs competitors
How KRRO compares with its peers on the latest reported figures
- KRRO's Mar 2026 total non-current assets of $63.46M is the highest of the 11 companies compared; the peer median is $15.72M.
- Its year-over-year change of -21.6% is the 8th highest of 11, against a peer median of -11.6%.
- Total non-current assets amounts to 34.6% of total assets for KRRO, versus a peer median of 5.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $63.46M | -21.6% | +23.2% | 34.6% | |
ENGNenGene Holdings Inc. | Apr 2026 | $37.52M | -3.0% | -46.6% | 12.2% |
| Mar 2026 | $34.62M | -0.7% | -1.5% | 13.2% | |
| Mar 2026 | $19.75M | -76.1% | -52.7% | 3.1% | |
| Mar 2026 | $19.7M | -8.0% | -3.9% | 7.4% | |
| Mar 2026 | $19.17M | -8.2% | -10.2% | 13.9% | |
| Mar 2026 | $12.27M | -20.9% | +5.7% | 10.7% | |
| Mar 2026 | $7.13M | -15.0% | +62.2% | 2.6% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $4.41M | -1.3% | +1044.9% | 1.1% |
| Mar 2026 | $3.53M | -24.6% | -12.3% | 1.7% | |
| Mar 2026 | $954K | -52.3% | -50.3% | 0.3% | |
| Peer median (excluding KRRO) | $15.72M | -11.6% | -7.1% | 5.2% | |
Competitors are the stored peer set for KRRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 79.64M | 36.94M | 166.15M | 55.64M | 21.82M |
| Short-term Investments | 51.07M | 18.92M | 0 | 70.45M | 53.33M |
| Net Receivables | 144K | 0 | 0 | 1.7M | 969K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 1.04M | (376K) | 3.56M | 3.74M | 6.25M |
| Total Current Assets | 134.75M | 57.08M | 172.73M | 131.53M | 82.37M |
| Property, Plant & Equipment (Net) | 36.87M | 11.89M | 42.82M | 51.55M | 16.22M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 13.42M | 4.54M | 3.41M | 36.96M | 12.44M |
| Tax Assets | 0 | 0 | 0 | 0 | 2.2M |
| Other Non-current Assets | 320K | 228K | 2.71M | 6.2M | 270K |
| Total Non-current Assets | 50.61M | 16.66M | 48.94M | 94.71M | 31.13M |
| Total Assets | 185.36M | 73.74M | 221.66M | 226.24M | 113.51M |
| Account Payables | 2.75M | 2.61M | 7.28M | 3.99M | 1.65M |
| Short-term Debt | 2.58M | 2.92M | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 3.51M | 7.84M |
| Other Current Liabilities | 1.73M | 551K | 395K | 4.05M | (3.72M) |
| Total Current Liabilities | 11.43M | 8.7M | 19.48M | 14.96M | 11.94M |
| Long-term Debt | 14.17M | 163.86M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 5.91M | 7.84M |
| Other Non-current Liabilities | 87K | 163.86M | 1.05M | 1.47M | 1.48M |
| Total Non-current Liabilities | 43.11M | 164.07M | 32.27M | 50.87M | 50.13M |
| Total Liabilities | 54.53M | 172.77M | 51.75M | 65.83M | 62.07M |
| Common Stock | 35K | 0 | 8K | 9K | 9K |
| Retained Earnings | (180.09M) | (101.83M) | (183.01M) | (266.59M) | (383.85M) |
| Accumulated OCI | (62K) | (5K) | (0) | 268K | 212K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 130.82M | (99.03M) | 169.91M | 160.42M | 51.44M |
| Total Debt | 45.6M | 166.99M | 33.21M | 44.77M | 43.49M |
| Net Debt | (34.04M) | 130.06M | (132.94M) | (10.88M) | 21.66M |
Korro Bio, Inc.
NASDAQ:KRRO
Intrinsic Alpha fair value
Locked
Current Price
$12.44
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.